FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1846-1848 April 27, 2006 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Davis, J. M. Related Article by Honer, W. G. PubMed Citation

To the Editor: Honer et al. (Feb. 2 issue)¹ showed that clozapine augmented with risperidone is unlikely to yield a moderate-to-large effect in patients with refractory schizophrenia. They conclude that there is no support for antipsychotic polypharmacy, a view also apparent in the accompanying editorial by Davis.² However, their confidence interval for the difference in the change in scores on the Positive and Negative Syndrome Scale still includes small-to-moderate effect sizes (0.3 to 0.5). Given the individual suffering and economic burden due to schizophrenia,³ we think that even a moderate effect of combined treatment is worth considering. Moreover, although the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.